The KRAS G12D selective inhibitor MRTX-1133 was assessed in combination with cirtuvivint in four PDMR lines harboring the KRAS G12D mutation and the 616215-338-R-J1 colon carcinoma which harbors a KRAS G12S mutation (Fig. 2) [24]. The gene discussed is KRAS; the disease is colon carcinoma.